Effect of botulinum toxin concentration on reduction in sweating: A randomized, double-blind study

Acta Dermato-Venereologica

Volumn 93, Issue 6, 2013, Pages 674-678

  Rystedt, Alma ^a   Karlqvist, Mattias ^a   Bertilsson, Maria ^b   Naver, Hans ^a,c   Swartling, Carl ^a,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Nyköping Hospital   (Sweden)

^d ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

Botox; Botulinum toxin; Dysport; Hyperhidrosis; Neurobloc; Xeomin

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; IODINE; STARCH;

ADULT; AGED; ANHIDROSIS; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FEMALE; HUMAN; HYPERHIDROSIS; INTRACUTANEOUS TEST; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN EXAMINATION; SWEATING;

ADULT; AGED; BACK; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; SWEATING; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886435689     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1606     Document Type: Article

References (22)

1. Iwase S, Ikeda T, Kitazawa H, Hakusui S, Sugenoya J, Mano T. Altered response in cutaneous sympathetic outflow to mental and thermal stimuli in primary palmoplantar hyperhidrosis. J Autonom Nervous System 1997; 64: 65-73.
2. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001; 20: 127-136.
3. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-462.
4. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64: 6-12.
5. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-1018.
6. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235: 197-199.
7. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 1995; 2: 17-18.
8. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-1446.
9. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438.
10. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29: 7-13; discussion 13.
11. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007; 67: 669-683.
12. Rystedt A, Swartling C, Naver H. Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations. Acta Derm Venereol 2008; 88: 229-233.
13. Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 2009; 24: 231-236.
14. Minor V. Ein neues verfahren zu der klinischen untersuchung der schweissabsonderung. Deutche Z Fur Nervenheilkunde 1927; 101: 302-306.
15. Birklein F, Eisenbarth G, Erbguth F, Winterholler M. Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up. J Invest Dermatol 2003; 121: 1312-1316.
16. Kranz G, Paul A, Voller B, Posch M, Windischberger C, Auff E, et al. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. Br J Dermatol 2011; 164: 176-181.
17. Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 2002; 249: 1729-1732.
18. Rystedt A, Swartling C, Farnstrand C, Naver H. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis. Acta Derm Venereol 2008; 88: 458-461.
19. Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 335-340.
20. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 2006; 13 Suppl 1: 11-15.
21. Albanese A. Discussion of unique properties of botulinum toxins. Toxicon 2009; 54: 702-708.
22. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Current Med Res Opin 2009; 25: 1573-1584.